Using multi-omics to improve diagnosis and treatment of urinary system tumors
The Research Value of Multi-omics and Multi-modal Information in the Diagnosis and Treatment of Urinary System Tumors
This study is trying to collect and analyze tumor samples from patients with bladder, kidney, and prostate cancers to see if new techniques can help improve how we diagnose and treat these tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06490211 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect tumor tissue samples from patients diagnosed with urinary system carcinomas, including bladder, kidney, and prostate cancers. The study will utilize advanced techniques such as RNA-sequencing, single-cell RNA-sequencing, spatial transcriptomics, proteomics, and analysis of the intratumoral microbiome to gather comprehensive biological data. By integrating these multi-omics and multi-modal approaches, the study seeks to enhance understanding of tumor biology and improve diagnostic and treatment strategies for affected patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have been treated for bladder, kidney, or prostate cancer and have confirmed diagnoses through tissue biopsy.
Not a fit: Patients with poor image quality, incomplete clinical data, or other primary malignant tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and personalized treatment options for patients with urinary system tumors.
How similar studies have performed: While multi-omics approaches are gaining traction, this specific integration of techniques in urinary system tumors is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients were treated for bladder cancer, kidney cancer, and prostate cancer in Wuhan Union Hospital from January 2024 to January 2026; 2. Aged \> 18 years old; 3. Urinalysis, urine exfoliated cells, ultrasound, CT, and MR examinations indicated the above tumors; 4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors. Exclusion Criteria: 1. Poor image quality; 2. Incomplete clinical data or loss of follow-up; 3. Presence of another primary malignant tumor other than urinary tract tumor; 4. Unclear pathological diagnosis
Where this trial is running
Wuhan, Hubei
- Union Hospital，Tongji Medical College，Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
Study contacts
- Study coordinator: Lian Yang
- Email: yanglian@hust.edu.cn
- Phone: 18986273791
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.